Rapid Micro Biosystems (RPID) Accounts Payables (2020 - 2026)

Rapid Micro Biosystems has disclosed Accounts Payables across 7 years of filings, most recently posting $4.7 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.7 million, up 77.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (up 77.23% YoY), and the FY2025 annual result was $4.1 million, up 63.27% from the prior year.
• Accounts Payables came in at $4.7 million for Q1 2026 at Rapid Micro Biosystems, up from $4.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.4 million in Q4 2022 to a low of $1.2 million in Q1 2024.
• The 5-year median for Accounts Payables is $2.8 million (2022), against an average of $2.9 million.
• Across the five-year window, Accounts Payables tumbled 63.75% in 2023 and surged 126.37% in 2025, its largest moves.
• Rapid Micro Biosystems' Accounts Payables stood at $5.4 million in 2022, then tumbled by 63.65% to $2.0 million in 2023, then advanced by 28.48% to $2.5 million in 2024, then surged by 63.27% to $4.1 million in 2025, then increased by 12.83% to $4.7 million in 2026.
• The last three Accounts Payables figures came in at $4.7 million (Q1 2026), $4.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.